Shares of Aurobindo Pharma Ltd were trading in the green and 1.8% higher on 23 December after the company’s step-down subsidiary, CuraTeQ Biologics s.r.o., announced securing marketing approval from the UK’s Medicines and Healthcare Products Regulatory Agency’s (MHRA)  for Bevqolva, its bevacizumab biosimilar version.

Bevqolva 25 mg/mL concentrate will be available in single-use vials containing 4 mL (100 mg) and 16 mL (400 mg) for intravenous infusion.

Numerous cancers can be treated with bevacizumab, including advanced and/or metastatic renal cell carcinoma, metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer, and more.

Last week, the United States Food and Drug Administration (USFDA) issued two observations following its inspection of the Unit-V API manufacturing facility at Apitoria Pharma, a wholly owned subsidiary of the company, situated in Pashamylaram Village, Telangana. The inspection took place between 9 December and 17 December 2024.

Earlier this month, the Medicinal Products for Human Use (CHMP) committee of the European Medicines Agency (EMA) expressed a favourable opinion for the filgrastim biosimilar Zefylti (BP13), recommending that CuraTeQ Biologics, the company’s subsidiary, be given a marketing license.

Furthermore, Eugia Pharma Specialities, the company’s wholly owned subsidiary, has received final approval from the USFDA to manufacture and market 200 mg Pazopanib Tablets, which are therapeutically and bioequivalent to Votrient Tablets, the reference listed drug (RLD) of Novartis Pharmaceuticals Corporation. The product is expected to launch in the fourth quarter of FY25.

At 11:23 am, the shares of Aurobindo Pharma were trading 1.32% higher at Rs 1,258.10 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!